Breast cancer (Tokyo, Japan)最新文献

{"title":"Prognostic and monitoring value of circulating tumor DNA at multiple clinical time points in breast cancer.","authors":"Min-Seung Park, Youngjin Youn, Jee Ah Kim, Eun Hye Cho, In-Gu Do, Hee-Yeon Woo, Hyosoon Park, Eun Young Kim, Min-Jung Kwon","doi":"10.1007/s12282-025-01818-z","DOIUrl":"10.1007/s12282-025-01818-z","url":null,"abstract":"<p><strong>Background: </strong>Circulating tumor DNA (ctDNA) has emerged as a prognostic biomarker for breast cancer, potentially offering a more comprehensive representation of tumor genetic heterogeneity. In this study, we assessed the prognostic and monitoring values of ctDNA at multiple clinical time points during diagnosis and therapy.</p><p><strong>Methods: </strong>A total of 119 patients with breast cancer underwent ctDNA analysis using next-generation sequencing, targeting 47 breast cancer-related genes at three predefined time points (baseline, post-neoadjuvant chemotherapy [post-NAC], and follow-up). Disease-free survival (DFS) was analyzed based on ctDNA status.</p><p><strong>Results: </strong>ctDNA was detected in 50.9% of patients at baseline, 25.0% post-NAC, and 58.3% during follow-up. ctDNA positivity was associated with worse DFS at baseline (hazard ratio [HR] 7.54, 95% CI: 1.71-33.17, P = 0.008), post-NAC (HR 3.54, 95% CI: 1.24-10.12, P = 0.018), and follow-up (HR 7.68, 95% CI: 0.98-59.97, P = 0.052). TP53 mutations were the most frequently observed, present in 37.5%, 14.8%, and 20.4% of patients at baseline, post-NAC, and follow-up, respectively. PIK3CA mutations were the second most common, detected in 11.6%, 4.5%, and 5.8% of patients, respectively. ctDNA positivity for these mutations consistently showed elevated HRs for disease progression across clinical time points (HR range, 2.73-20.49). ctDNA non-clearance was associated with the highest risk of disease progression (HR 81.09, P < 0.001) and remained the strongest independent prognostic factor in the multivariate analysis (HR 52.07, P < 0.001).</p><p><strong>Conclusions: </strong>ctDNA analysis provides significant clinical utility for prognostic stratification and disease monitoring in breast cancer management.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"377-385"},"PeriodicalIF":2.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146095399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-effectiveness analysis of the Oncotype DX Breast Recurrence Score^® test among node-negative early breast cancer patients in Japan.","authors":"Kei Koizumi, Ataru Igarashi, Mark Gouldson, Sandeep Bilthare, Sebastien Eymere, Gebra Cuyún-Carter, Steve Millen, Mariko Nomoto, Yoshie Onishi, Aki Kudo, Pieter Drost, Naoko Sugiyama, Tom Kanazawa Tang, Naoki Niikura","doi":"10.1007/s12282-026-01834-7","DOIUrl":"10.1007/s12282-026-01834-7","url":null,"abstract":"","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"499-509"},"PeriodicalIF":2.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12960466/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146198392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real world experience of intraoperative radiation therapy (IORT) during lumpectomy for early-stage breast cancer: retrospective data from a single large institutional observational study.","authors":"Christophe Scherer, Vivien Fung, Dimitri Anzellini, Mattia Falchettto Osti, Virginie Doridot, Xavier Muracciole, Mario Nappa, Benoît Mesurolle, Gokoulakrichenane Loganadane","doi":"10.1007/s12282-026-01824-9","DOIUrl":"10.1007/s12282-026-01824-9","url":null,"abstract":"<p><strong>Background: </strong>We report outcomes of patients who received intraoperative radiation therapy (IORT) using 50 kV after lumpectomy and sentinel lymph node biopsy.</p><p><strong>Methods: </strong>Women with age > 45 and post-menopausal status, localized, unifocal, invasive breast carcinoma were included in the study. Patients were diagnosed by needle biopsy, and suitable for wide local excision of invasive ductal carcinoma without nodal involvement on conventional examination (cT1 and small cT2 ≤ 3.5 cm, cN0, M0). Overall, 489 patients who received adjuvant IORT after breast-conserving surgery were identified between March 2016 to June 2023. The median age was 68 years (range 49-93). The median tumor size was 8 mm (0-40 mm). Adjuvant whole breast adiation therapy (WBRT), chemotherapy and endocrine were additionally offered in 36 patients (7.4%), 12 (2.4%) and 384 patients (78.5%) respectively.</p><p><strong>Results: </strong>After a median follow-up of 36 months (range, 0-100), the 3-year LR was 1.4% (95% CI 0.6-3.1%). The 3-year LRFS, LRRFS, and PFS were each 97.1% (95% CI 94.6-98.5%), while the 3-year MRFS and OS were both 98.3% (95% CI 96.1-99.2%). The 3-year outcomes did not differ significantly between the IORT and IORT + WBRT cohorts. Patients who did not receive ET (n = 104) experienced a significantly higher rate of local recurrence compared with those who received ET (n = 384) (3-year LR 4.0% vs. 0.7%; p = 0.01). LRFS and LRRFS showed borderline significance (5-year LRFS 96.9% vs. 100%; p = 0.05). MRFS, PFS, and OS did not differ significantly between the two groups.</p><p><strong>Conclusions: </strong>Preliminary 3-year results show that IORT with 50 kV achieves excellent local control in selected early-stage breast cancer patients. Endocrine therapy reduced local recurrence, while WBRT added no significant benefit, underscoring the need for longer follow-up.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"426-435"},"PeriodicalIF":2.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146042417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Infiltration of TIM4-positive intratumoral macrophages serves as an adverse prognostic factor in breast cancer.","authors":"Mio Yamaguchi-Tanaka, Kiyoshi Takagi, Miyu Takahashi, Ai Sato, Yuto Yamazaki, Minoru Miyashita, Takashi Suzuki","doi":"10.1007/s12282-026-01825-8","DOIUrl":"10.1007/s12282-026-01825-8","url":null,"abstract":"<p><strong>Background: </strong>T-cell immunoglobulin and mucin domain containing protein 4 (TIM4), a phosphatidylserine receptor primarily expressed on antigen-presenting cells, has been implicated in phagocytosis and immune regulation in various diseases, including malignancies. However, the significance of TIM4 in the breast cancer microenvironment remains unclear. In this study, we investigated the localization and clinical significance of TIM4 in breast cancer.</p><p><strong>Methods: </strong>We immunolocalized TIM4 in human breast carcinoma tissues using immunohistochemistry (IHC) and multiplex fluorescence-immunohistochemistry (F-IHC) and examined its correlation with clinicopathological parameters and clinical outcomes.</p><p><strong>Results: </strong>TIM4 was highly expressed in both carcinoma cells and stromal cells in human breast carcinoma tissues. Multiplex F-IHC revealed that TIM4 was co-localized with CD68, a macrophage marker, whereas no co-localization was observed between TIM4 and CD80 (an M1 macrophage marker) or CD163 (an M2 macrophage marker). Prognostic analysis of 171 breast carcinoma tissues by IHC revealed that infiltration of TIM4-positive stromal cells was associated with an aggressive tumor phenotype, including increased proliferative and invasive potential, as well as poorer clinical outcomes. In contrast, TIM4 immunoreactivity in carcinoma cells showed no significant correlation with clinical outcomes.</p><p><strong>Conclusions: </strong>These findings suggest that infiltration of TIM4-positive macrophages serves as a strong prognostic indicator in breast cancer and that TIM4 may represent a novel marker for tumor-promoting macrophages.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"436-447"},"PeriodicalIF":2.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12960482/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146014099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A novel quantification method for automatic computation of breast density from mammography images using deep learning.","authors":"Kenichi Inoue, Aika Kawasaki, Takeshi Sasaki, Takako Doi","doi":"10.1007/s12282-025-01808-1","DOIUrl":"10.1007/s12282-025-01808-1","url":null,"abstract":"","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"324-332"},"PeriodicalIF":2.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12960319/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145947022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Overall survival of palbociclib plus endocrine therapy in Japanese patients with HR+/HER2- advanced breast cancer in the first-or second-line setting: a multicenter observational study (P-BRIDGE study).","authors":"Shigenori E Nagai, Masaya Hattori, Tetsuhiro Yoshinami, Hiroko Masuda, Takuho Okamura, Kenichi Watanabe, Takahiro Nakayama, Michiko Tsuneizumi, Daisuke Takabatake, Michiko Harao, Hiroshi Yoshino, Natsuko Mori, Hiroyuki Yasojima, Chiya Oshiro, Madoka Iwase, Miki Yamaguchi, Takafumi Sangai, Shinsuke Sasada, Takanori Ishida, Manabu Futamura, Yasuaki Muramatsu, Nobuyoshi Kosaka, Norikazu Masuda","doi":"10.1007/s12282-025-01787-3","DOIUrl":"10.1007/s12282-025-01787-3","url":null,"abstract":"","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"559-568"},"PeriodicalIF":2.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12960297/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146055843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world analysis of interstitial lung disease/pneumonitis in Japanese patients with breast cancer receiving trastuzumab deruxtecan.","authors":"Junji Tsurutani, Kengo Noguchi, Ayumi Tanabe","doi":"10.1007/s12282-025-01814-3","DOIUrl":"10.1007/s12282-025-01814-3","url":null,"abstract":"","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"346-358"},"PeriodicalIF":2.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12960362/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146095328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"tRNA modification genes are associated with genomic instability, proliferative programs, and poor prognosis in breast cancer.","authors":"Yusuke Otani, Atsushi Tanaka, Anna Rogachevskaya, Akira Ohtsu, Vanessa D Chin, Tirso Peña, Shinichi Toyooka, Hiroyoshi Doihara, Atsushi Fujimura","doi":"10.1007/s12282-026-01830-x","DOIUrl":"10.1007/s12282-026-01830-x","url":null,"abstract":"","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"523-535"},"PeriodicalIF":2.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146133991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of the postoperative prognostication tool PREDICT version 2.2 and 3.0 using data from the National cancer center hospital in Japan.","authors":"Hiromi Hashiguchi, Nobuji Kouno, Masaaki Komatsu, Sho Shiino, Naoto Takehara, Katsuji Takeda, Satoshi Takahashi, Yi-Wen Hsiao, Takeshi Murata, Kazutaka Obama, Shin Takayama, Paul D P Pharoah, Ryuji Hamamoto","doi":"10.1007/s12282-026-01823-w","DOIUrl":"10.1007/s12282-026-01823-w","url":null,"abstract":"<p><strong>Background: </strong>PREDICT is a prognostic tool developed in the United Kingdom to estimate postoperative overall survival (OS) and the additional benefits of adjuvant therapies in patients with breast cancer. It has been validated in various international cohorts and continuously updated with the inclusion of new variables and model retraining. However, their efficacy in the Japanese population remains unclear. We aimed to evaluate the generalizability of PREDICT versions 2.2 (v2.2) and 3.0 (v3.0) using data from the National Cancer Center Hospital in Japan, a high-volume cancer center.</p><p><strong>Methods: </strong>We analyzed a retrospective cohort (2006-2016) including 2,980 cases of postoperative breast cancer. We calculated survival predictions using both v2.2 and v3.0, and compared them with the Kaplan-Meier-estimated survival probabilities using a calibration plot. Additionally, we performed a time-dependent receiver operating characteristic (ROC) curve analysis for v2.2 and v3.0.</p><p><strong>Results: </strong>Both models tended to underestimate survival in our cohort, whereas v3.0 showed improved calibration compared to v2.2, for 5- and 10-year OS. Both v2.2 and v3.0 maintained good discriminative performance throughout 10 years, with values under the ROC curve generally above 0.80.</p><p><strong>Conclusions: </strong>Despite these differences, both versions demonstrated satisfactory performance, suggesting that they can be generalized for Japanese patients with postoperative breast cancer. Notably, v3.0, given its improved calibration, might be more suitable for supporting shared decision making. The model's performance in predicting 5-year OS supports its generalizability, whereas 10-year projections warrant caution due to limited follow-up. Overall, this study demonstrates that PREDICT is a valuable prognostic tool for Japanese patients with breast cancer.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"415-425"},"PeriodicalIF":2.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12960381/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146000474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An investigation to identify the factors for negative sentinel lymph node metastasis in early breast cancer cases.","authors":"Reiki Nishimura, Yuichi Ueda, Hiroshi Kiyohara, Mayumi Funagayama, Naoko Ikeda, Aya Kato, Hideaki Tokiniwa, Ryutaro Higashi, Mayumi Nakahara, Hiromi Ifuku, Tohru Hayashi, Yasuaki Sagara, Yoshiaki Sagara, Shinji Ohno","doi":"10.1007/s12282-026-01832-9","DOIUrl":"10.1007/s12282-026-01832-9","url":null,"abstract":"","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"536-543"},"PeriodicalIF":2.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146145895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}